Non-Alcoholic Fatty Liver Disease (NAFLD), recently renamed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is a condition where excess fat accumulates in the liver without significant alcohol use. It affects an estimated 30-40% of the Indian urban population, making it the most common liver disorder in India. The condition ranges from simple fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH), which can progress to fibrosis, cirrhosis, and liver cancer. Indians are particularly susceptible due to high rates of insulin resistance, central obesity, and a carbohydrate-heavy diet.
Causes & Risk Factors#
- Insulin resistance and metabolic syndrome: the primary driver; closely linked to Type 2 diabetes.
- Obesity, especially central adiposity: even "lean NAFLD" is common in Indians with normal BMI but high abdominal fat.
- High-carbohydrate, high-fructose diet: excessive rice, maida, sugar, and sweetened beverages drive hepatic fat accumulation.
- Sedentary lifestyle: lack of exercise reduces fat oxidation in the liver.
- Genetic factors: PNPLA3 gene variants are more common in South Asians, increasing susceptibility.
Signs & Symptoms#
- Usually asymptomatic in early stages, often discovered incidentally on ultrasound
- Vague right upper abdominal discomfort or heaviness
- Fatigue and low energy levels
- Unexplained weight gain, especially around the abdomen
- Elevated liver enzymes on routine blood tests
- In advanced stages: jaundice, abdominal swelling (ascites), easy bruising
- Dark patches on the skin (acanthosis nigricans) indicating insulin resistance
Diagnosis#
- Liver Function Test (LFT): ALT and AST may be mildly elevated (ALT > AST pattern in NAFLD). Book Liver Function Test
- Abdominal Ultrasound: the most common initial test; shows increased liver echogenicity graded as Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe).
- FibroScan (Transient Elastography): measures liver stiffness to assess fibrosis non-invasively.
- FIB-4 Index: a simple score using age, AST, ALT, and platelet count to estimate fibrosis risk.
- Lipid Profile, Fasting Glucose, HbA1c: to assess metabolic comorbidities. Book Lipid Profile, Book HbA1c
Treatment Options#
No FDA-approved drug exists specifically for NAFLD. Lifestyle modification is the primary treatment:
- Weight loss: losing 7-10% of body weight can resolve NASH and improve fibrosis. Even 3-5% weight loss reduces liver fat.
- Diet: Replace white rice with millets and whole grains, reduce sugar and maida, increase vegetables and protein, avoid sugary drinks and fruit juices, limit fructose (including excess fruit).
- Exercise: 150-200 minutes/week of moderate-intensity exercise (brisk walking, cycling, swimming). Both aerobic and resistance training reduce liver fat independently of weight loss.
- Medications for comorbidities: Metformin for diabetes, statins for dyslipidemia (safe in NAFLD), vitamin E (800 IU/day) for non-diabetic NASH under medical guidance.
- Avoid alcohol completely: even small amounts worsen fatty liver.
Prevention#
- Maintain a healthy waist circumference (< 90 cm men, < 80 cm women for Indians).
- Limit added sugars to < 25 g/day. Avoid sweetened beverages, packaged juices, and excess jaggery.
- Choose whole grains over refined carbohydrates at every meal.
- Exercise regularly, even 30 minutes of daily walking provides benefit.
- Get annual liver function tests if you have metabolic risk factors.
When to See a Doctor#
Consult a gastroenterologist/hepatologist if your ultrasound shows fatty liver Grade 2 or above, if liver enzymes are persistently elevated, or if you have diabetes or obesity with fatty liver. Seek urgent care if you develop jaundice, abdominal swelling, or vomiting blood, these suggest advanced liver disease.